Patent intelligence · US
US 10576095
Use of aminoglycoside analogs in the treatment of Rett syndrome
Use of aminoglycoside analogs in the treatment of Rett syndrome
Patent details — US 10576095
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 3, 2020
- Expiration
- Feb 27, 2040
- Applicant
- ELOXX PHARMACEUTICALS LTD.
- Claims
- 30
- CPC classes
- A61K, A61K31/7036, A61P, A61P25/00
Quick answer
US 10576095 (Use of aminoglycoside analogs in the treatment of Rett syndrome) is held by ELOXX PHARMACEUTICALS LTD.. Status: granted. Granted Mar 3, 2020. Expires Feb 27, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ELOXX PHARMACEUTICALS LTD.
- Grant date
- Expiration
- Claims
- 30
- CPC classes
- A61K, A61K31/7036, A61P, A61P25/00, A61P43/00
More from ELOXX PHARMACEUTICALS LTD.
Related pharmaceutical patents in our USPTO index.
-
US 11786539
Aminoglycoside derivatives and uses thereof in treating genetic disorders
granted -
US 11613551
Aminoglycoside derivatives and uses thereof in treating genetic disorders
granted -
US 11306115
Aminoglycoside derivatives and uses thereof in treating genetic disorders
granted -
US 10899785
Aminoglycoside derivatives and uses thereof in treating genetic disorders
granted -
US 10786520
Aminoglycoside derivatives and uses thereof in treating genetic disorders
granted
Frequently asked questions
What is US patent 10576095?
US 10576095 (Use of aminoglycoside analogs in the treatment of Rett syndrome) is held by ELOXX PHARMACEUTICALS LTD.. Status: granted. Granted Mar 3, 2020. Expires Feb 27, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10576095?
ELOXX PHARMACEUTICALS LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 10576095 expire?
Our index shows an expiration date of Feb 27, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.